Loading...
Please wait, while we are loading the content...
Similar Documents
Scan Rituximab for childhood-onset , complicated , frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome : a multicentre
| Content Provider | Semantic Scholar |
|---|---|
| Copyright Year | 2015 |
| Abstract | Journal Scan Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, doubleblind, randomised, placebo-controlled trial This was a multicentre, double-blind, randomised, placebo-controlled trial at nine centres in Japan. Patients aged 2 years or more experiencing a relapse of frequently relapsing nephrotic syndrome (FRNS) or steroid dependant nephrotic syndrome (SDNS) were recruited. Patients were randomly assigned to receive rituximab (375 mg/m) or placebo once weekly for 4 weeks. All patients received standard steroid treatment for the relapse at screening and stopped taking immunosuppressive agents by 169 days after randomisation. Patients were followed up for 1 year. Of 52 patients who underwent randomisation, 48 received the assigned intervention (24 were given rituximab and 24 placebo). The median relapse-free period was significantly longer in the rituximab group (267 days, 95% CI 223-374) than in the placebo group (101 days, 70-155; hazard ratio: 0·27, 0·14-0·53; p<0·0001). Ten patients (42%) in the rituximab group and six (25%) in the placebo group had at least one serious adverse event (p=0·36). Comment |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://svimstpt.ap.nic.in/jcsr/jan-mar15_files/js41.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
